Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  16 results for ""Cyclic Nucleotide Phosphodiesterases, Type 3""

Your Filters

Subject : phosphodiesterase 4 inhibitors
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay.

  • Authors : Zhao P; School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.; Chen SK

Subjects: Cyclic Nucleotide Phosphodiesterases, Type 3/Cyclic Nucleotide Phosphodiesterases, Type 3/Cyclic Nucleotide Phosphodiesterases, Type 3/*chemistry ; Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/*chemistry ; Plant Extracts/Plant Extracts/Plant Extracts/*chemistry

  • Source: Biochimica et biophysica acta [Biochim Biophys Acta] 2013 Oct; Vol. 1834 (10), pp. 2089-96. Date of Electronic Publication: 2013 Jul 19.Publisher: Elsevier Pub. Co Country of Publication: Netherlands NLM ID: 0217513 Publication Model: Print-Electronic Cited Medium: Print ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Dual Inhibition of Phosphodiesterase 3 and 4 Enzymes by Ensifentrine Protects against MRSA-Induced Lung Endothelial and Epithelial Dysfunction.

  • Authors : Al Matni MY; Division of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois Chicago, Chicago, IL 60612, USA.; Meliton L

Subjects: Methicillin-Resistant Staphylococcus aureus*/Methicillin-Resistant Staphylococcus aureus*/Methicillin-Resistant Staphylococcus aureus*/drug effects ; Phosphodiesterase 4 Inhibitors*/Phosphodiesterase 4 Inhibitors*/Phosphodiesterase 4 Inhibitors*/pharmacology ; Endothelial Cells*/Endothelial Cells*/Endothelial Cells*/drug effects

  • Source: Cells [Cells] 2024 Oct 23; Vol. 13 (21). Date of Electronic Publication: 2024 Oct 23.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409

Record details

Read More Add to Saved list
×
Academic Journal

The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants.

  • Authors : Turner MJ; Department of Physiology, McGill University, Montreal, Quebec, Canada.; Cystic Fibrosis Translational Research Centre, McGill University, Montreal, Quebec, Canada.

Subjects: Cyclic AMP/Cyclic AMP/Cyclic AMP/*metabolism ; Cystic Fibrosis Transmembrane Conductance Regulator/Cystic Fibrosis Transmembrane Conductance Regulator/Cystic Fibrosis Transmembrane Conductance Regulator/*genetics ; Isoquinolines/Isoquinolines/Isoquinolines/*pharmacology

  • Source: American journal of physiology. Lung cellular and molecular physiology [Am J Physiol Lung Cell Mol Physiol] 2020 May 01; Vol. 318 (5), pp. L908-L920. Date of Electronic Publication: Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901229 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Single inhibition of either PDE3 or PDE4 unmasks β2-adrenoceptor-mediated inotropic and lusitropic effects in the left but not right ventricular myocardium of rat.

  • Authors : Soler F; Department of Biochemistry and Molecular Biology A, University of Murcia, 30100 Murcia, Spain. Electronic address: .; Fernández-Belda F

Subjects: Myocardial Contraction/Myocardial Contraction/Myocardial Contraction/*physiology ; Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/*pharmacology ; Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/*pharmacology

  • Source: European journal of pharmacology [Eur J Pharmacol] 2015 Oct 15; Vol. 765, pp. 429-36. Date of Electronic Publication: 2015 Sep 11.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.

Subjects: Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/*therapeutic use ; Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/*therapeutic use ; Respiratory Tract Diseases/Respiratory Tract Diseases/Respiratory Tract Diseases/*drug therapy

  • Source: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2014 May; Vol. 114 (5), pp. 365-76. Date of Electronic Publication: 2014 Mar 06.Publisher: Blackwell Country of Publication: England NLM ID: 101208422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1742-7843

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.

  • Authors : Ochiai K; Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd, 2399-1 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.; Takita S

Subjects: Anti-Inflammatory Agents/Anti-Inflammatory Agents/Anti-Inflammatory Agents/*chemistry ; Bronchodilator Agents/Bronchodilator Agents/Bronchodilator Agents/*chemistry ; Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/*chemistry

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2013 Jan 01; Vol. 23 (1), pp. 375-81. Date of Electronic Publication: 2012 Nov 09.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.

  • Authors : Gobejishvili L; Department of Internal Medicine (L.G., S.B., J.Z., D.V.A., C.J.M.) and Department of Pharmacology and Toxicology (S.B., D.V.A., C.J.M.), University of Louisville, Louisville, Kentucky; Department of Surgery, University of Louisville Medical Center, Louisville, Kentucky (Y.L.)

Subjects: Bile Duct Diseases/Bile Duct Diseases/Bile Duct Diseases/*prevention & control ; Cyclic Nucleotide Phosphodiesterases, Type 4/Cyclic Nucleotide Phosphodiesterases, Type 4/Cyclic Nucleotide Phosphodiesterases, Type 4/*physiology ; Liver Cirrhosis, Experimental/Liver Cirrhosis, Experimental/Liver Cirrhosis, Experimental/*pathology

  • Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2013 Oct; Vol. 347 (1), pp. 80-90. Date of Electronic Publication: 2013 Jul 25.Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

PDE3 and PDE4 isozyme-selective inhibitors are both required for synergistic activation of brown adipose tissue.

  • Authors : Kraynik SM; Department of Pharmacology, University of Washington, Seattle, WA, USA.; Miyaoka RS

Subjects: Adipose Tissue, Brown/Adipose Tissue, Brown/Adipose Tissue, Brown/*drug effects ; Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/Phosphodiesterase 3 Inhibitors/*pharmacology ; Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/Phosphodiesterase 4 Inhibitors/*pharmacology

  • Source: Molecular pharmacology [Mol Pharmacol] 2013 Jun; Vol. 83 (6), pp. 1155-65. Date of Electronic Publication: 2013 Mar 14.Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0035623 Publication Model:

Record details

Read More Add to Saved list
×
Academic Journal

Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio.

Subjects: Asthma/Asthma/Asthma/*physiopathology ; Bronchial Hyperreactivity/Bronchial Hyperreactivity/Bronchial Hyperreactivity/*drug therapy ; Cyclic Nucleotide Phosphodiesterases, Type 4/Cyclic Nucleotide Phosphodiesterases, Type 4/Cyclic Nucleotide Phosphodiesterases, Type 4/*metabolism

  • Source: Journal of biomedical science [J Biomed Sci] 2011 Nov 11; Vol. 18, pp. 84. Date of Electronic Publication: 2011 Nov 11.Publisher: BioMed Central Country of Publication: England NLM ID: 9421567 Publication Model: Electronic Cited Medium: Internet ISSN: 1423-0127

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.

  • Authors : Ochiai K; Discovery Research Laboratories, Kyorin Pharmaceutical Co. Ltd, 2399-1 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.; Ando N

Subjects: Drug Design*; Anti-Inflammatory Agents, Non-Steroidal/Anti-Inflammatory Agents, Non-Steroidal/Anti-Inflammatory Agents, Non-Steroidal/*pharmacology ; Bronchodilator Agents/Bronchodilator Agents/Bronchodilator Agents/*pharmacology

  • Source: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2011 Sep 15; Vol. 21 (18), pp. 5451-6. Date of Electronic Publication: 2011 Jul 02.Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  16 results for ""Cyclic Nucleotide Phosphodiesterases, Type 3""